UltraSight

📍 Cambridge, United States🗓 Founded 2018👥 35 employees💰 Last funded Aug 2024
UltraSight aims to revolutionize cardiac sonography through the power of machine learning to enable more accurate and timely clinical decisions. UltraSight’s AI-driven software provides real-time guidance and quality assessment to allow healthcare professionals, regardless of sonography proficiency, to consistently perform high-quality cardiac ultrasound in a variety of settings at the point of care, including clinics, community hospitals, ambulances, and remote and rural areas. UltraSight’s AI real-time guidance software has FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR Clearance to assist medical professionals in performing cardiac ultrasound scans. UltraSight’s software is an accessory to compatible general-purpose, diagnostic ultrasound systems. Full labeling is available at https://ultrasight.com/regulatory-approvals-and-labeling/. In 2022, UltraSight won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most "innovative cardiac technology." Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices.
3
Total investors
0
Early stage
1
Mid stage
2
Late stage
2018
Founded
Investor geography2 countries
Israel
2
United States
1
Investor activity2021–2024 · investors recorded per year
2021120242
Recent (last 2y)Earlier
Frequently asked questions
Who invested in UltraSight?
UltraSight has 3 investors on record on gritt.io, 1 mid-stage and 2 late-stage investors.
When did UltraSight last raise funding?
The most recent investment in UltraSight recorded on gritt.io was in August 2024.
When was UltraSight founded?
UltraSight was founded in 2018.
What industry is UltraSight in?
UltraSight operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is UltraSight based?
UltraSight is headquartered in Cambridge, United States.